Beta Drugs Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: May 6, 2025, 12:59 am

Market Cap	1,787 Cr.
Current Price	1,770
High / Low	2,215/1,048
Stock P/E	43.6
Book Value	179
Dividend Yield	0.00 %
ROCE	32.8 %
ROE	26.0 %
Face Value	10.0
PEG Ratio	1.53

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Beta Drugs Ltd

Competitors of Beta Drugs Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	158 Cr.	112	247/84.3	22.8	36.5	0.00 %	18.0 %	15.5 %	10.0
MPS Pharmaa Ltd	5.24 Cr.	2.74	4.33/2.71		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	41.2 Cr.	55.5	94.9/44.5	14.0	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	28.4 Cr.	19.4	29.0/13.1	29.0	6.64	0.00 %	2.65 %	2.08 %	10.0
Industry Average	18,518.26 Cr	1,097.47		42.98	183.01	0.33%	15.93%	16.74%	6.19

All Competitor Stocks of Beta Drugs Ltd

Quarterly Result

Metric	Sep 2019	Mar 2020	Sep 2020	Mar 2021	Sep 2021	Mar 2022	Sep 2022	Mar 2023	Sep 2023	Mar 2024	Sep 2024
Sales	47	44	51	65	88	96	112	115	141	154	180
Expenses	37	36	41	51	68	73	86	88	108	127	141
Operating Profit	9	8	11	14	20	23	27	26	33	27	39
OPM %	20%	19%	21%	22%	23%	24%	24%	23%	23%	18%	22%
Other Income	0	0	0	0	0	0	0	0	1	1	2
Interest	1	2	1	1	1	1	1	1	1	1	2
Depreciation	2	2	3	4	3	4	5	6	5	4	6
Profit before tax	7	5	7	9	16	18	21	20	27	22	33
Tax %	27%	14%	21%	30%	28%	27%	25%	25%	25%	25%	25%
Net Profit	5	4	5	7	12	13	16	15	20	17	24
EPS in Rs	5.33	4.46	5.39	6.80	12.22	13.61	16.47	15.48	20.67	17.23	25.42

Last Updated: March 3, 2025, 5:18 pm

Below is a detailed analysis of the quarterly data for Beta Drugs Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Sales, as of Sep 2024, the value is 180.00 Cr.. The value appears strong and on an upward trend. It has increased from 154.00 Cr. (Mar 2024) to 180.00 Cr., marking an increase of 26.00 Cr..
For Expenses, as of Sep 2024, the value is 141.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 127.00 Cr. (Mar 2024) to 141.00 Cr., marking an increase of 14.00 Cr..
For Operating Profit, as of Sep 2024, the value is 39.00 Cr.. The value appears strong and on an upward trend. It has increased from 27.00 Cr. (Mar 2024) to 39.00 Cr., marking an increase of 12.00 Cr..
For OPM %, as of Sep 2024, the value is 22.00%. The value appears strong and on an upward trend. It has increased from 18.00% (Mar 2024) to 22.00%, marking an increase of 4.00%.
For Other Income, as of Sep 2024, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2024) to 2.00 Cr., marking an increase of 1.00 Cr..
For Interest, as of Sep 2024, the value is 2.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.00 Cr. (Mar 2024) to 2.00 Cr., marking an increase of 1.00 Cr..
For Depreciation, as of Sep 2024, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.00 Cr. (Mar 2024) to 6.00 Cr., marking an increase of 2.00 Cr..
For Profit before tax, as of Sep 2024, the value is 33.00 Cr.. The value appears strong and on an upward trend. It has increased from 22.00 Cr. (Mar 2024) to 33.00 Cr., marking an increase of 11.00 Cr..
For Tax %, as of Sep 2024, the value is 25.00%. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 25.00%.
For Net Profit, as of Sep 2024, the value is 24.00 Cr.. The value appears strong and on an upward trend. It has increased from 17.00 Cr. (Mar 2024) to 24.00 Cr., marking an increase of 7.00 Cr..
For EPS in Rs, as of Sep 2024, the value is 25.42. The value appears strong and on an upward trend. It has increased from 17.23 (Mar 2024) to 25.42, marking an increase of 8.19.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: May 3, 2025, 3:04 pm

Metric	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	51	66	91	116	184	227	296	335
Expenses	41	54	73	91	141	174	236	269
Operating Profit	9	12	18	25	43	53	60	66
OPM %	19%	18%	20%	21%	23%	23%	20%	20%
Other Income	0	0	0	0	1	1	1	2
Interest	1	1	3	2	2	2	3	3
Depreciation	2	3	4	7	7	10	10	10
Profit before tax	7	8	12	16	34	41	49	55
Tax %	1%	-2%	21%	27%	28%	25%	25%
Net Profit	7	8	9	12	25	31	36	41
EPS in Rs	7.43	8.84	9.33	11.60	24.58	30.42	36.08	40.60
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	14.29%	12.50%	33.33%	108.33%	24.00%	16.13%
Change in YoY Net Profit Growth (%)	0.00%	-1.79%	20.83%	75.00%	-84.33%	-7.87%

Beta Drugs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2018-2019 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	%
5 Years:	35%
3 Years:	37%
TTM:	31%

Compounded Profit Growth
10 Years:	%
5 Years:	35%
3 Years:	46%
TTM:	18%

Stock Price CAGR
10 Years:	%
5 Years:	106%
3 Years:	26%
1 Year:	43%

Return on Equity
10 Years:	%
5 Years:	26%
3 Years:	28%
Last Year:	26%

Last Updated: Unknown

Balance Sheet

Last Updated: November 15, 2024, 1:36 am

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	9	9	10	10	10	10	10	10
Reserves	24	32	48	59	83	113	148	171
Borrowings	8	20	23	17	21	20	15	19
Other Liabilities	9	22	28	31	45	55	82	95
Total Liabilities	50	83	107	118	158	198	254	295
Fixed Assets	13	18	44	40	55	63	65	66
CWIP	1	15	0	3	0	0	0	0
Investments	0	0	0	1	1	1	0	0
Other Assets	35	50	63	74	102	135	190	229
Total Assets	50	83	107	118	158	198	254	295

Below is a detailed analysis of the balance sheet data for Beta Drugs Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.00 Cr..
For Reserves, as of Sep 2024, the value is ₹171.00 Cr.. The value appears strong and on an upward trend. It has increased from 148.00 Cr. (Mar 2024) to ₹171.00 Cr., marking an increase of 23.00 Cr..
For Borrowings, as of Sep 2024, the value is ₹19.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 15.00 Cr. (Mar 2024) to ₹19.00 Cr., marking an increase of 4.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹95.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 82.00 Cr. (Mar 2024) to ₹95.00 Cr., marking an increase of 13.00 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹295.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 254.00 Cr. (Mar 2024) to ₹295.00 Cr., marking an increase of 41.00 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹66.00 Cr.. The value appears strong and on an upward trend. It has increased from 65.00 Cr. (Mar 2024) to ₹66.00 Cr., marking an increase of 1.00 Cr..
For CWIP, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
For Investments, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹229.00 Cr.. The value appears strong and on an upward trend. It has increased from 190.00 Cr. (Mar 2024) to ₹229.00 Cr., marking an increase of 39.00 Cr..
For Total Assets, as of Sep 2024, the value is ₹295.00 Cr.. The value appears strong and on an upward trend. It has increased from 254.00 Cr. (Mar 2024) to ₹295.00 Cr., marking an increase of 41.00 Cr..

Notably, the Reserves (171.00 Cr.) exceed the Borrowings (19.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	17	0	8	19	30	23	31
Cash from Investing Activity +	-11	-21	-15	-6	-22	-19	-14
Cash from Financing Activity +	5	12	9	-8	-1	-2	-7
Net Cash Flow	12	-9	2	5	7	2	9

Free Cash Flow

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	1.00	-8.00	-5.00	8.00	22.00	33.00	45.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Debtor Days	104	139	128	106	90	101
Inventory Days	37	104	102	100	87	106
Days Payable	81	143	119	127	123	139
Cash Conversion Cycle	60	100	111	79	53	68
Working Capital Days	75	100	95	88	70	88
ROCE %		18%	21%	22%	36%	34%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Promoters	66.68%	66.71%	66.71%	66.71%	66.71%	66.71%	66.73%	66.73%	66.73%	66.73%	66.73%	66.73%
FIIs	0.00%	0.00%	0.00%	0.00%	0.29%	0.29%	0.29%	0.29%	0.32%	0.32%	0.32%	0.90%
DIIs	0.28%	0.29%	0.29%	0.29%	0.04%	0.04%	0.04%	0.04%	0.02%	0.02%	0.06%	0.12%
Public	33.03%	33.01%	33.00%	33.00%	32.96%	32.96%	32.94%	32.93%	32.93%	32.92%	32.87%	32.25%
No. of Shareholders	542	675	762	1,296	1,407	1,444	1,424	1,451	1,722	1,928	2,116	2,323

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	37.90	31.95	25.82	12.20	9.93
Diluted EPS (Rs.)	37.90	31.95	25.82	12.20	9.93
Cash EPS (Rs.)	48.08	42.78	33.37	19.34	13.70
Book Value[Excl.RevalReserv]/Share (Rs.)	163.43	127.82	96.05	71.37	59.41
Book Value[Incl.RevalReserv]/Share (Rs.)	163.43	127.82	96.05	71.37	59.41
Revenue From Operations / Share (Rs.)	307.59	236.24	191.22	120.79	94.45
PBDIT / Share (Rs.)	63.82	56.05	45.20	26.26	19.05
PBIT / Share (Rs.)	53.65	45.22	37.65	19.11	15.14
PBT / Share (Rs.)	50.71	42.70	35.68	16.59	12.45
Net Profit / Share (Rs.)	37.90	31.95	25.82	12.20	9.79
NP After MI And SOA / Share (Rs.)	37.90	31.95	25.82	12.20	9.79
PBDIT Margin (%)	20.74	23.72	23.63	21.73	20.17
PBIT Margin (%)	17.44	19.14	19.69	15.81	16.03
PBT Margin (%)	16.48	18.07	18.65	13.73	13.18
Net Profit Margin (%)	12.32	13.52	13.50	10.09	10.36
NP After MI And SOA Margin (%)	12.32	13.52	13.50	10.09	10.36
Return on Networth / Equity (%)	23.19	24.99	26.88	17.08	16.48
Return on Capital Employeed (%)	30.43	32.10	33.24	22.09	20.65
Return On Assets (%)	14.33	15.48	15.72	9.97	8.78
Long Term Debt / Equity (X)	0.03	0.05	0.12	0.16	0.17
Total Debt / Equity (X)	0.06	0.13	0.17	0.21	0.34
Asset Turnover Ratio (%)	1.31	1.27	1.09	0.82	0.79
Current Ratio (X)	2.10	2.03	1.98	1.99	1.53
Quick Ratio (X)	1.51	1.54	1.52	1.53	1.19
Inventory Turnover Ratio (X)	4.17	4.16	5.70	4.47	4.43
Interest Coverage Ratio (X)	21.76	22.31	22.88	10.43	7.08
Interest Coverage Ratio (Post Tax) (X)	13.92	13.72	14.07	5.85	4.64
Enterprise Value (Cr.)	1168.47	599.62	542.92	119.61	52.99
EV / Net Operating Revenue (X)	3.95	2.64	2.95	1.03	0.58
EV / EBITDA (X)	19.04	11.13	12.49	4.74	2.89
MarketCap / Net Operating Revenue (X)	4.01	2.65	2.96	0.99	0.42
Price / BV (X)	7.55	4.90	5.89	1.68	0.67
Price / Net Operating Revenue (X)	4.01	2.65	2.96	0.99	0.42
EarningsYield	0.03	0.05	0.04	0.10	0.24

After reviewing the key financial ratios for Beta Drugs Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 24, the value is 37.90. This value is within the healthy range. It has increased from 31.95 (Mar 23) to 37.90, marking an increase of 5.95.
For Diluted EPS (Rs.), as of Mar 24, the value is 37.90. This value is within the healthy range. It has increased from 31.95 (Mar 23) to 37.90, marking an increase of 5.95.
For Cash EPS (Rs.), as of Mar 24, the value is 48.08. This value is within the healthy range. It has increased from 42.78 (Mar 23) to 48.08, marking an increase of 5.30.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 163.43. It has increased from 127.82 (Mar 23) to 163.43, marking an increase of 35.61.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 163.43. It has increased from 127.82 (Mar 23) to 163.43, marking an increase of 35.61.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 307.59. It has increased from 236.24 (Mar 23) to 307.59, marking an increase of 71.35.
For PBDIT / Share (Rs.), as of Mar 24, the value is 63.82. This value is within the healthy range. It has increased from 56.05 (Mar 23) to 63.82, marking an increase of 7.77.
For PBIT / Share (Rs.), as of Mar 24, the value is 53.65. This value is within the healthy range. It has increased from 45.22 (Mar 23) to 53.65, marking an increase of 8.43.
For PBT / Share (Rs.), as of Mar 24, the value is 50.71. This value is within the healthy range. It has increased from 42.70 (Mar 23) to 50.71, marking an increase of 8.01.
For Net Profit / Share (Rs.), as of Mar 24, the value is 37.90. This value is within the healthy range. It has increased from 31.95 (Mar 23) to 37.90, marking an increase of 5.95.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 37.90. This value is within the healthy range. It has increased from 31.95 (Mar 23) to 37.90, marking an increase of 5.95.
For PBDIT Margin (%), as of Mar 24, the value is 20.74. This value is within the healthy range. It has decreased from 23.72 (Mar 23) to 20.74, marking a decrease of 2.98.
For PBIT Margin (%), as of Mar 24, the value is 17.44. This value is within the healthy range. It has decreased from 19.14 (Mar 23) to 17.44, marking a decrease of 1.70.
For PBT Margin (%), as of Mar 24, the value is 16.48. This value is within the healthy range. It has decreased from 18.07 (Mar 23) to 16.48, marking a decrease of 1.59.
For Net Profit Margin (%), as of Mar 24, the value is 12.32. This value exceeds the healthy maximum of 10. It has decreased from 13.52 (Mar 23) to 12.32, marking a decrease of 1.20.
For NP After MI And SOA Margin (%), as of Mar 24, the value is 12.32. This value is within the healthy range. It has decreased from 13.52 (Mar 23) to 12.32, marking a decrease of 1.20.
For Return on Networth / Equity (%), as of Mar 24, the value is 23.19. This value is within the healthy range. It has decreased from 24.99 (Mar 23) to 23.19, marking a decrease of 1.80.
For Return on Capital Employeed (%), as of Mar 24, the value is 30.43. This value is within the healthy range. It has decreased from 32.10 (Mar 23) to 30.43, marking a decrease of 1.67.
For Return On Assets (%), as of Mar 24, the value is 14.33. This value is within the healthy range. It has decreased from 15.48 (Mar 23) to 14.33, marking a decrease of 1.15.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.03. This value is below the healthy minimum of 0.2. It has decreased from 0.05 (Mar 23) to 0.03, marking a decrease of 0.02.
For Total Debt / Equity (X), as of Mar 24, the value is 0.06. This value is within the healthy range. It has decreased from 0.13 (Mar 23) to 0.06, marking a decrease of 0.07.
For Asset Turnover Ratio (%), as of Mar 24, the value is 1.31. It has increased from 1.27 (Mar 23) to 1.31, marking an increase of 0.04.
For Current Ratio (X), as of Mar 24, the value is 2.10. This value is within the healthy range. It has increased from 2.03 (Mar 23) to 2.10, marking an increase of 0.07.
For Quick Ratio (X), as of Mar 24, the value is 1.51. This value is within the healthy range. It has decreased from 1.54 (Mar 23) to 1.51, marking a decrease of 0.03.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 4.17. This value is within the healthy range. It has increased from 4.16 (Mar 23) to 4.17, marking an increase of 0.01.
For Interest Coverage Ratio (X), as of Mar 24, the value is 21.76. This value is within the healthy range. It has decreased from 22.31 (Mar 23) to 21.76, marking a decrease of 0.55.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 13.92. This value is within the healthy range. It has increased from 13.72 (Mar 23) to 13.92, marking an increase of 0.20.
For Enterprise Value (Cr.), as of Mar 24, the value is 1,168.47. It has increased from 599.62 (Mar 23) to 1,168.47, marking an increase of 568.85.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 3.95. This value exceeds the healthy maximum of 3. It has increased from 2.64 (Mar 23) to 3.95, marking an increase of 1.31.
For EV / EBITDA (X), as of Mar 24, the value is 19.04. This value exceeds the healthy maximum of 15. It has increased from 11.13 (Mar 23) to 19.04, marking an increase of 7.91.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 4.01. This value exceeds the healthy maximum of 3. It has increased from 2.65 (Mar 23) to 4.01, marking an increase of 1.36.
For Price / BV (X), as of Mar 24, the value is 7.55. This value exceeds the healthy maximum of 3. It has increased from 4.90 (Mar 23) to 7.55, marking an increase of 2.65.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 4.01. This value exceeds the healthy maximum of 3. It has increased from 2.65 (Mar 23) to 4.01, marking an increase of 1.36.
For EarningsYield, as of Mar 24, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 23) to 0.03, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Beta Drugs Ltd as of May 6, 2025 is: 1,655.78

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of May 6, 2025, Beta Drugs Ltd is Overvalued by 6.45% compared to the current share price 1,770.00

Intrinsic Value of Beta Drugs Ltd as of May 6, 2025 is: 2,127.24

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of May 6, 2025, Beta Drugs Ltd is Undervalued by 20.18% compared to the current share price 1,770.00

Last 5 Year EPS CAGR: 28.47%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 18.71%, which is a positive sign. The company has higher reserves (84.75 cr) compared to borrowings (17.88 cr), indicating strong financial stability. The company has shown consistent growth in sales (170.75 cr) and profit (27.75 cr) over the years.	The stock has a high average Working Capital Days of 73.71, which may not be favorable. The stock has a high average Cash Conversion Cycle of 67.29, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Beta Drugs Ltd:
1. Net Profit Margin: 12.32%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 30.43% (Industry Average ROCE: 15.8%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 23.19% (Industry Average ROE: 16.19%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 13.92
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.51
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 43.6 (Industry average Stock P/E: 34.17)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.06
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Beta Drugs Ltd. is a Public Limited Listed company incorporated on 21/09/2015 and has its registered office in the State of Himachal Pradesh, India. Company's Corporate Identification Number(CIN) is L24230HP2005PLC028969 and registration number is 028969. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 197.62 Cr. and Equity Capital is Rs. 9.61 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Village Nandpur, Baddi Himachal Pradesh 174101	cs@betadrugslimited.com http://www.betadrugslimited.com

Management
Name	Position Held
Mr. Rahul Batra	Chairperson & Managing Director
Mr. Varun Batra	Joint Managing Director
Mrs. Seema Chopra	Whole Time Director
Mr. Balwant Singh	Whole Time Director
Mr. Manmohan Khanna	Independent Director
Mr. Ashutosh Shukla	Whole Time Director
Mr. Rohit Parti	Independent Director

FAQ

What is the intrinsic value of Beta Drugs Ltd?

Beta Drugs Ltd's intrinsic value (as of 06 May 2025) is ₹1655.78 — 6.45% lower the current market price of 1,770.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,787 Cr. market cap, FY2025-2026 high/low of ₹2,215/1,048, reserves of 171 Cr, and liabilities of 295 Cr.

What is the Market Cap of Beta Drugs Ltd?

The Market Cap of Beta Drugs Ltd is 1,787 Cr..

What is the current Stock Price of Beta Drugs Ltd as on 06 May 2025?

The current stock price of Beta Drugs Ltd as on 06 May 2025 is 1,770.

What is the High / Low of Beta Drugs Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Beta Drugs Ltd stocks is ₹2,215/1,048.

What is the Stock P/E of Beta Drugs Ltd?

The Stock P/E of Beta Drugs Ltd is 43.6.

What is the Book Value of Beta Drugs Ltd?

The Book Value of Beta Drugs Ltd is 179.

What is the Dividend Yield of Beta Drugs Ltd?

The Dividend Yield of Beta Drugs Ltd is 0.00 %.

What is the ROCE of Beta Drugs Ltd?

The ROCE of Beta Drugs Ltd is 32.8 %.

What is the ROE of Beta Drugs Ltd?

The ROE of Beta Drugs Ltd is 26.0 %.

What is the Face Value of Beta Drugs Ltd?

The Face Value of Beta Drugs Ltd is 10.0.